- CertainT to Be Deployed to Ensure Material
and Product Authenticity, Origin, Traceability, Sustainability, and
Quality -
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the
"Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA
manufacturing that enables in vitro diagnostics, pre-clinical
nucleic acid-based therapeutic drug candidates, supply chain
security, anti-counterfeiting and anti-theft technology, today
announced it has entered into a supply agreement (the “Agreement”)
for its CertainT® platform with ITW Pillar Technologies (“Pillar”),
a division of Illinois Tool Works (ITW).
Under the terms of the Agreement, Applied DNA will supply
SigNature® molecular tags and SigNify® in-field authentication
devices to Pillar for use on materials and products treated with
Pillar’s patented plasma deposition technology. Said materials and
products will carry Applied DNA’s CertainT trademark, representing
authenticity, origin, traceability, sustainability, and quality
that will bring transparency to Pillar’s customers’ supply chains
and enable these customers to promote traceability and trust in the
materials used in their products. Pillar’s systems are utilized by
many of the leading manufacturers of N95 masks, gowns, and other
equipment used by frontline healthcare practitioners. Plasma
deposition technology allows for the finishing of textiles that
imparts varying enhanced characteristics – wickability,
breathability, ink and dye uptake, anti-microbial, hydrophobicity,
etc. – that are ecofriendly to apply relative to traditional
wet-chemical processes. The Agreement supports Pillar’s strategy to
combat the growing issue of counterfeit PPE entering the healthcare
supply chain as the COVID-19 pandemic increases demand and has
grown to include other materials and products manufactured by
Pillar’s customers.
Pillar personnel will be fully trained in the application of the
unique molecular tags and in the use of the in-field authentication
systems. Pillar will incorporate SigNature molecular tags into
textiles including, but not limited to, polypropylene, cotton,
recycled polyester, nylon, wool, and viscose for the manufacture of
products, including those used in the manufacture of personal
protective equipment (PPE). Authentication of all tagged materials
and products will be tracked via CertainT’s cloud-based portal for
ease of access by Pillar and its customers.
“We believe our partnership with Applied DNA in the deployment
of its CertainT platform across our manufacturing lines provides
brands and manufacturers the most advanced and secure plasma-based
systems available on the market globally. As the standard of proof
and need for greater transparency continues to increase, so too
does the need to have a scientific basis to support sustainability
goals and ongoing commercial programs. Our customers now have the
complete solution that gives them formidable brand protection and
assurance with forensic certainty,” said Rory Wolf, CEO of
ITW Pillar Technologies. “We are especially pleased to offer
definitive proof of the authenticity of PPE materials to customers
at a time when COVID-19-fueled demand has led to an influx of
substandard and falsified product in the healthcare supply
chain.”
Commenting on the Agreement, MeiLin Wan, VP, Textiles at Applied
DNA, stated, “Pillar represents further adoption of our CertainT
platform and another avenue for the commercialization of our supply
chain security solutions. Having validated and proven that our
CertainT platform can work on a wide range of substrates with
Pillar, the advancement in portable testing together with
advancements in non-chemical applications for textiles and other
materials provides a compelling solution for branded and
proprietary products that require a trusted, market-ready
solution.”
About CertainT
The CertainT® platform has three technology pillars (Tag, Test,
Track) which allows raw materials and products to be tagged with a
unique molecular identifier. This identifier can then be tested for
its presence as it travels throughout a global supply chain. All
the data points associated to tagging and testing are tracked by
uploading to a secure cloud database. The platform can be used
across industries such as textiles, cannabis, military, leather,
fertilizer, pharmaceuticals, personal care.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping and pre-clinical nucleic acid-based
therapeutic drug candidates.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
The Company’s common stock is listed on NASDAQ under ticker
symbol ‘APDN’, and its publicly traded warrants are listed on OTC
under ticker symbol ‘APPDW’.
Applied DNA is a member of the Russell Microcap® Index.
About ITW Pillar Technologies
Founded in 1966, Pillar Technologies leads the industry in new
product development for the packaging, converting and plastic
film-printing marketplace. As a division of ITW, our company has
access to literally hundreds of products manufactured by many
business units within the family.
ITW businesses serve local customers and markets around the
globe, with a significant presence in developed as well as emerging
markets. The company has operations in 55 countries that employ
more than 48,000 women and men who adhere to the highest ethical
standards. These talented individuals, many of whom have
specialized engineering or scientific expertise, contribute to our
global leadership in innovation. We are proud of our broad
portfolio of more than 17,000 granted and pending patents.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934 and the Private Securities Litigation Reform Act of
1995. Forward-looking statements describe Applied DNA’s future
plans, projections, strategies and expectations, and are based on
assumptions and involve a number of risks and uncertainties, many
of which are beyond the control of Applied DNA. Actual results
could differ materially from those projected due to the possibility
of a failure to make timely payment on its outstanding secured
convertible notes and resulting enforcement by noteholders of
remedies on collateral which includes substantially all of Applied
DNA’s assets, its history of net losses, limited financial
resources, limited market acceptance, the uncertainties inherent in
research and development, future clinical data and analysis,
including whether any of Applied DNA’s or its partners diagnostic
or therapeutic candidates will advance further in the preclinical
research or clinical trial process, including receiving clearance
from the U.S. Food and Drug Administration or equivalent foreign
regulatory agencies to conduct clinical trials and whether and
when, if at all, they will receive final approval from the U.S. FDA
or equivalent foreign regulatory agencies, the unknown outcome of
any applications to U.S. FDA or equivalent foreign regulatory
agencies, our ability to successfully enter into commercial
contracts for the implementation of our CertainT® platform and
various other factors detailed from time to time in Applied DNA’s
SEC reports and filings, including our Annual Report on Form 10-K
filed on December 12, 2019 and our subsequent quarterly report on
Form 10-Q filed on February 6, 2020, May 14, 2020 and August 6,
2020, and other reports we file with the SEC, which are available
at www.sec.gov. Applied DNA undertakes no obligation to update
publicly any forward-looking statements to reflect new information,
events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events, unless otherwise required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200921005162/en/
Investors: Sanjay M. Hurry, Applied DNA Sciences,
917.733.5573, sanjay.hurry@adnas.com Media: MeiLin Wan,
Applied DNA Sciences, meilin.wan@adnas.com Rory Wolf, ITW Pillar
Technologies, rwolf@pillartech.com Web: www.adnas.com,
www.pillartech.com Twitter: @APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024